E. Imyanitov, Gene polymorphisms, apoptotic capacity and cancer risk, Human Genetics, vol.61, issue.3, pp.239-246, 2009.
DOI : 10.1007/s00439-009-0636-7

G. Dasika, S. Lin, S. Zhao, P. Sung, A. Tomkinson et al., DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis, Oncogene, vol.18, issue.55, pp.7883-99, 1999.
DOI : 10.1038/sj.onc.1203283

E. Pietsch, O. Humbey, and M. Murphy, Polymorphisms in the p53 pathway, Oncogene, vol.25, issue.11, pp.1602-1611, 2006.
DOI : 10.1038/366701a0

C. Whibley, P. Pharoah, and M. Hollstein, p53 polymorphisms: cancer implications, Nature Reviews Cancer, vol.382, issue.2, pp.95-107, 2009.
DOI : 10.1038/ncb1802

P. Dumont, J. Leu, D. Pietra, A. George, D. Murphy et al., The codon 72 polymorphic variants of p53 have markedly different apoptotic potential, Nature Genetics, vol.33, issue.3, pp.357-65, 2003.
DOI : 10.1038/ng1093

E. Hallani, S. Ducray, F. Idbaih, A. Marie, Y. Boisselier et al., TP53 codon 72 polymorphism is associated with age at onset of glioblastoma, Neurology, vol.72, issue.4, pp.332-338, 2009.
DOI : 10.1212/01.wnl.0000341277.74885.ec

R. Hrstka, P. Coates, and B. Vojtesek, Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment, Journal of Cellular and Molecular Medicine, vol.137, issue.3, pp.440-453, 2009.
DOI : 10.1111/j.1582-4934.2008.00634.x

D. Oliveira, W. Rady, P. Grady, J. Hughes, T. Neto et al., Association of p53 arginine polymorphism with skin cancer, International Journal of Dermatology, vol.62, issue.7, pp.489-93, 2004.
DOI : 10.1016/S0140-6736(94)92343-4

S. Cattelani, G. Ferrari-amorotti, S. Galavotti, R. Defferrari, B. Tanno et al., The p53 Codon 72 Pro/Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients: Correlation with Reduced Apoptosis and Enhanced Senescence by the p53-72P Isoform, Neoplasia, vol.14, issue.7, pp.634-677, 2012.
DOI : 10.1593/neo.12594

M. Siddique, C. Balram, L. Fiszer-maliszewska, A. Aggarwal, A. Tan et al., Evidence for Selective Expression of the p53 Codon 72 Polymorphs: Implications in Cancer Development, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.9, pp.2245-52, 2005.
DOI : 10.1158/1055-9965.EPI-05-0153

A. Damin, A. Frazzon, D. Damin, A. Roehe, V. Hermes et al., Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk, Cancer Detection and Prevention, vol.30, issue.6, pp.523-529, 2006.
DOI : 10.1016/j.cdp.2006.09.007

Y. Hu, M. Mcdermott, and S. Ahrendt, The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.11, issue.7, pp.2502-2509, 2005.
DOI : 10.1158/1078-0432.CCR-04-1913

A. Storey, M. Thomas, A. Kalita, C. Harwood, D. Gardiol et al., Role of a p53 polymorphism in the development of human papillomavirus associated cancer p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients, Nature. Pharmacogenet Genomics, vol.393, issue.16, pp.229-234347, 1998.

V. Lima-ramos, L. Pacheco-figueiredo, S. Costa, F. Pardal, A. Silva et al., TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas, Cancer Genetics and Cytogenetics, vol.180, issue.1, pp.14-19, 2008.
DOI : 10.1016/j.cancergencyto.2007.08.019

S. Lambert, H. Witt, V. Hovestadt, M. Zucknick, M. Kool et al., Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma, Acta Neuropathologica, vol.129, issue.2, pp.291-301, 2013.
DOI : 10.1007/s00401-013-1124-7

C. Faria, J. Miguéns, J. Antunes, D. Salgado, S. Nunes et al., Pediatric brain tumors: genetics and clinical outcome, Journal of Neurosurgery: Pediatrics, vol.5, issue.3, pp.263-70, 2010.
DOI : 10.3171/2009.10.PEDS09240

P. Kaatsch, Epidemiology of childhood cancer, Cancer Treatment Reviews, vol.36, issue.4, pp.277-85, 2010.
DOI : 10.1016/j.ctrv.2010.02.003

A. Gnekow, F. Falkenstein, S. Von-hornstein, I. Zwiener, S. Berkefeld et al., Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology, Neuro-Oncology, vol.14, issue.10, pp.1265-84, 2012.
DOI : 10.1093/neuonc/nos202

D. Louis, H. Ohgaki, O. Wiestler, W. Cavenee, P. Burger et al., The 2007 WHO Classification of Tumours of the Central Nervous System, Acta Neuropathologica, vol.64, issue.2, pp.97-109, 2007.
DOI : 10.1007/s00401-007-0243-4

D. Hargrave, Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy, British Journal of Neurosurgery, vol.106, issue.15, pp.351-63, 2009.
DOI : 10.1016/S1470-2045(06)70615-5

J. Kraus, J. Felsberg, J. Tonn, G. Reifenberger, and T. Pietsch, Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood, Neuropathology and Applied Neurobiology, vol.12, issue.4, pp.325-358, 2002.
DOI : 10.1002/(SICI)1097-0215(19960503)66:3<305::AID-IJC6>3.3.CO;2-1

I. Pollack, J. Biegel, A. Yates, R. Hamilton, and S. Finkelstein, Risk assignment in childhood brain tumors: The emerging role of molecular and biologic classification, Current Oncology Reports, vol.343, issue.2, pp.114-136, 2002.
DOI : 10.1007/s11912-002-0072-5

M. Olivier, R. Eeles, M. Hollstein, M. Khan, C. Harris et al., The IARC TP53 database: New online mutation analysis and recommendations to users, Human Mutation, vol.61, issue.6, pp.607-621, 2002.
DOI : 10.1002/humu.10081

I. Pollack, S. Finkelstein, J. Burnham, E. Holmes, R. Hamilton et al., Sposto R; Children's Cancer Group Age and TP53 Mutation Frequency in Childhood Malignant Gliomas: results in a multiinstitutional cohort, Cancer Res, vol.61, pp.7404-7407, 2001.

V. Hayes, C. Dirven, A. Dam, E. Verlind, W. Molenaar et al., in the Development of These Tumors, Brain Pathology, vol.6, issue.3, pp.463-470, 1999.
DOI : 10.1111/j.1750-3639.1999.tb00535.x

A. Broniscer, S. Baker, A. West, M. Fraser, E. Proko et al., Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children, Journal of Clinical Oncology, vol.25, issue.6, pp.682-691, 2007.
DOI : 10.1200/JCO.2006.06.8213

S. Patt, H. Gries, M. Giraldo, J. Cervos-navarro, H. Martin et al., p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas, Human Pathology, vol.27, issue.6, pp.586-595, 1996.
DOI : 10.1016/S0046-8177(96)90166-5

P. Parhar, R. Ezer, Y. Shao, J. Allen, D. Miller et al., Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas, Molecular Brain Research, vol.137, issue.1-2, pp.98-103, 2005.
DOI : 10.1016/j.molbrainres.2005.02.016

A. Idbaih, B. Boisselier, Y. Marie, E. Hallani, S. Sanson et al., TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors, TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors, pp.103-107, 2007.
DOI : 10.1016/j.cancergencyto.2007.06.010
URL : https://hal.archives-ouvertes.fr/inserm-00310509

A. Petitjean, M. Achatz, A. Borresen-dale, P. Hainaut, and M. Olivier, TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes, Oncogene, vol.47, issue.15, pp.2157-65, 2007.
DOI : 10.1158/1078-0432.CCR-05-0507

G. Francisco, P. Menezes, J. Eluf-neto, and R. Chammas, Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies, International Journal of Cancer, vol.87, issue.4, pp.920-950, 2011.
DOI : 10.1002/ijc.25710

M. Shi, R. Huang, C. Pei, X. Jia, C. Jiang et al., TP53 codon 72 polymorphism and glioma risk: a meta-analysis, Oncol Lett, vol.3, pp.599-606, 2012.

H. Shen, A. Solari, X. Wang, Z. Zhang, Y. Xu et al., P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population, Oncology Reports, vol.11, pp.1115-1135, 2004.
DOI : 10.3892/or.11.5.1115

G. Beckman, R. Birgander, A. Själander, N. Saha, P. Holmberg et al., Is p53 polymorphism maintained by natural selection? Hum Hered, pp.266-70, 1994.
DOI : 10.1159/000154228

D. Bergamaschi, M. Gasco, L. Hiller, A. Sullivan, N. Syed et al., p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis, Cancer Cell, vol.3, issue.4, pp.387-402, 2003.
DOI : 10.1016/S1535-6108(03)00079-5

K. Jacob, D. Quang-khuong, D. Jones, H. Witt, S. Lambert et al., Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas, Clinical Cancer Research, vol.17, issue.14, pp.4650-60, 2011.
DOI : 10.1158/1078-0432.CCR-11-0127

D. Walker, A. Gnekow, G. Perilongo, and I. Zanetti, Vincristine (VCR) carboplatin (CBDCA) in hypothalamic-chiasmatic glioma (HCG): a report of the International Consortium on Low Grade Glioma (ICLGG) [abstract], Med Ped Oncol, vol.39, p.229, 2002.

D. Jones, B. Hutter, N. Jäger, A. Korshunov, M. Kool et al., Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma, Nature Genetics, vol.20, issue.8, pp.927-959, 2013.
DOI : 10.1006/jmbi.1993.1626

C. Chappé, L. Padovani, D. Scavarda, F. Forest, I. Nanni-metellus et al., Mutation and Expression, Brain Pathology, vol.360, issue.Pt 6, pp.574-83, 2013.
DOI : 10.1111/bpa.12048

S. Mascelli, A. Barla, A. Raso, S. Mosci, P. Nozza et al., Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas, BMC Cancer, vol.121, issue.6, p.387, 2013.
DOI : 10.1007/s00401-011-0802-6
URL : http://doi.org/10.1186/1471-2407-13-387

S. Mascelli, A. Raso, R. Biassoni, M. Severino, K. Sak et al., Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation, Journal of Neuro-Oncology, vol.154, issue.5, pp.477-84, 2012.
DOI : 10.1007/s11060-012-0925-1